Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst David Amsellem reiterated a Buy rating on Teva Pharmaceutical (TEVA) with a $42.00 price target. Amsellem, a 5-star analyst in the Healthcare sector, maintains this stance alongside an industry-wide Strong Buy consensus for Teva, which has an average price target of $42.38.
Piper Sandler analyst David Amsellem reiterated a Buy rating on Teva Pharmaceutical today and set a price target of $42.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Amsellem is a 5-star analyst with an average return of 14.8% and a 61.00% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Amgen, and Teva Pharmaceutical.
Currently, the analyst consensus on Teva Pharmaceutical is a Strong Buy with an average price target of $42.38.